OCR is actively working with Pharma/Biotech companies focused on Human Health on the conception and management of clinical trials (GCP) of Dogs & Cats with Naturally Occurring Pathologies for efficacy assessment of drug candidates for Human Health.
OCR is also working with major actor in the fields of Medical Device, Drug Delivery, Biosimilars, Nanotechnologies and Animal Health.
Our patients (dogs/cats) recruitment timings are short (2 months on average, depending on the protocole) and associated costs are much lower than those in human clinical.
Our innovative offer is at the forefront of ethics of research involving animals since Dogs & Cats included in clinical trials are treated as real patients with safe new therapies under development for Human.
Our main therapeutic field is Oncology (NH Lymphoma, Melanoma, Soft tissues sarcoma, Head & Neck Carcinoma, Osteosarcoma, Urogenital tumors, Mammary tumors, Brain & Spinal cord tumors, Prostatic tumor, Mast cell tumors…)
We also work on others therapeutic fields: Inflammation, Cardiology, Neurology, Pain Management, Metabolic & Respiratory diseases, Ophthalmology, Antibiotic resistance…
We propose to support drug development programs (in preclinical & clinical phases) in Oncology by getting key additional scientific information in high level predictive models of Human Cancers (Dogs & Cats with Natural Cancers).
Clinical trials of Dogs/Cats with Naturally Occurring Pathologies represent a new significant Decision-Making Tool in the Drug Development Process for human health (preclinical to clinical; activity; pharmacokinectics/dynamics; clinical strategy adjustment; dose; regimen; companion biomarker selection; MoA elucidation; new indication opportunities; combination therapies; drug delivery development).
Our specificity is to combine recognized experts in veterinary medicine, a multicenter recruitment network, a state of the art technical platform (histopathology lab. & advanced imaging devices) and high quality standards (ISO, ICH, FDA, CRF21 part 11…), applied to drug development for Human Health.
We also possess a fully characterized dog/cat tumors BioBank (Cry -80°C & FFPE), as well as a large panel of in vitro/ex vivo (mice, dogs, human) and in vivo (mice) models in oncology, residual disease and inflammation.